EGFR (Epidermal Growth Factor Receptor) signaling therapies represent an emerging approach in Parkinson's disease drug development that aims to provide neuroprotection to dopaminergic neurons in the substantia nigra pars compacta. Unlike dopamine replacement therapies that address symptoms, EGFR-targeted approaches seek to protect remaining neurons, support mitochondrial function, enhance autophagy, and potentially modify disease progression.
EGFR (Epidermal Growth Factor Receptor) signaling therapies represent an emerging approach in Parkinson's disease drug development that aims to provide neuroprotection to dopaminergic neurons in the substantia nigra pars compacta. Unlike dopamine replacement therapies that address symptoms, EGFR-targeted approaches seek to protect remaining neurons, support mitochondrial function, enhance autophagy, and potentially modify disease progression.
The rationale for EGFR signaling in Parkinson's disease stems from multiple lines of evidence: the receptor is widely expressed in dopaminergic neurons, EGFR activation promotes PI3K/Akt-mediated survival signaling, cross-talk exists with PD-related proteins (LRRK2, alpha-synuclein, GBA), and EGFR supports mitochondrial homeostasis and autophagy["@egfr_mechanism"][@egfr_review].
This category covers companies developing:
The EGFR and growth factor therapy field for Parkinson's disease has evolved from academic research to early commercial programs:
| Era | Focus | Status |
|-----|-------|--------|
| 1990s-2000s | Direct EGF protein infusion | Preclinical/Historic |
| 2010s | AAV gene therapy (GDNF, neurturin) | Clinical (mixed results) |
| 2020s | Small molecule modulators, cell therapy | Active development |
Key Challenges:
[Athira Pharma](/companies/athira-pharma) (NASDAQ: ATHA) is a clinical-stage company developing fosgonimeton (ATH-1017), a small molecule that targets the hepatocyte growth factor (HGF) system. While not directly targeting EGFR, the HGF/MET system shares significant overlap with EGFR signaling pathways in the brain and provides neuroprotective effects relevant to PD.
| Attribute | Details |
|-----------|---------|
| Lead Program | Fosgonimeton (ATH-1017) |
| Mechanism | HGF/MET receptor activator |
| Indication | Alzheimer's disease (with relevance to PD) |
| Stage | Phase 2/3 |
| Status | Recruiting |
Relevance to EGFR/PD: The HGF/MET system activates parallel PI3K/Akt and MAPK pathways similar to EGFR, promoting neuronal survival, synaptic function, and neurogenesis. While primarily developed for AD, the neuroprotective mechanisms are applicable to PD.
Mechanism: Fosgonimeton activates MET receptor, which promotes:
[SanBio Co., Ltd.](/companies/sanbio) (TSE: 4592) is a Japanese regenerative medicine company whose cell therapy platform secretes multiple neurotrophic factors including GDNF, BDNF, NGF, and VEGF. While not exclusively EGFR-targeted, the paracrine secretion profile includes factors that engage EGFR signaling pathways.
| Attribute | Details |
|-----------|---------|
| Lead Product | SB623 (AKUUGO®) |
| Technology | Allogeneic mesenchymal stromal cells |
| Indications | TBI, Stroke (with PD relevance) |
| Stage | Approved (Japan), Phase 2 |
| Headquarters | Tokyo, Japan |
Relevance to EGFR/PD: SB623 cells secrete neurotrophic factors that activate downstream EGFR signaling pathways:
[BrainStorm Cell Therapeutics](/companies/brainstorm-cell-therapeutics) (NASDAQ: BCLI) develops the NurOwn® platform, an autologous mesenchymal stromal cell therapy that secretes elevated levels of neurotrophic factors.
| Attribute | Details |
|-----------|---------|
| Lead Platform | NurOwn® |
| Technology | Autologous MSC-NTF cells |
| Indications | ALS (completed Phase 3), MS, PD (research) |
| Stage | Phase 3 completed (ALS) |
| Headquarters | New York, USA |
Relevance to EGFR/PD: NurOwn cells secrete GDNF, BDNF, VEGF, and HGF—all of which engage neuroprotective signaling pathways overlapping with EGFR. The company has conducted research in PD models.
Pipeline:
| Program | Indication | Phase | Status |
|---------|------------|-------|--------|
| NurOwn | ALS | Phase 3 | Completed |
| NurOwn | Progressive MS | Phase 1 | Active |
| NurOwn | Alzheimer's disease | Preclinical | Planning |
| NurOwn | Parkinson's disease | Research | Exploratory |
[Trefoil Therapeutics](/companies/trefoil-therapeutics) is a clinical-stage biotechnology company developing engineered neurotrophic factors with improved pharmacological properties.
| Attribute | Details |
|-----------|---------|
| Headquarters | Boston, Massachusetts |
| Founded | 2021 |
| Focus | Engineered neurotrophic factors |
| Funding | Series B ($55M, 2024) |
Pipeline:
| Drug | Mechanism | Indication | Stage |
|------|-----------|------------|-------|
| TF-201 | Synaptic growth factor | Alzheimer's disease | Phase 1 |
| TF-202 | Neuroprotective factor | Parkinson's disease | Preclinical |
TF-202 for PD: The company's second program specifically targets Parkinson's disease with a neuroprotective factor. While the exact mechanism is proprietary, engineered neurotrophic factors with EGFR-relevant signaling pathways are in development.
Engineering Advantages:
[Living Cell Technologies](/companies/living-cell-technologies) (ASX: LCT) developed NTCELL, an encapsulated cell therapy for Parkinson's disease that provides neurotrophic support through transplanted choroid plexus cells.
| Attribute | Details |
|-----------|---------|
| Product | NTCELL |
| Technology | Encapsulated choroid plexus cells |
| Indication | Parkinson's disease |
| Stage | Phase 1/2a completed |
| Headquarters | Sydney, Australia |
Relevance to EGFR/PD: Choroid plexus cells secrete multiple neurotrophic factors including GDNF and NGF, which engage PI3K/Akt survival pathways similar to EGFR signaling. The encapsulation technology allows sustained, localized delivery.
Clinical Outcomes:
[uniQure](/companies/uniqure) (NASDAQ: QURE) is a gene therapy company with an AAV platform that has explored GDNF delivery for Parkinson's disease.
| Attribute | Details |
|-----------|---------|
| Technology | AAV gene therapy |
| Focus | CNS disorders |
| Headquarters | Amsterdam, Netherlands / Lexington, Massachusetts |
| Ticker | QURE (NASDAQ) |
Relevance to EGFR/PD: While primarily focused on GDNF (which engages RET → PI3K/Akt pathways), the company's AAV platform is applicable to growth factor delivery for neuroprotection. EGFR ligand gene therapy (AAV-EGF) represents a potential approach.
Approach: AAV-mediated expression of neurotrophic factors (GDNF, BDNF, or EGF) in the striatum for sustained local delivery to dopaminergic neurons.
Drug discovery efforts are identifying brain-penetrant EGFR modulators for neurodegeneration:
| Company/Group | Approach | Stage |
|---------------|----------|-------|
| Academic consortia | BBB-penetrant EGFR agonists | Preclinical |
| Pharma R&D | Positive allosteric modulators | Discovery |
| Biotech startups | Tyrosine kinase agonists | Early development |
Challenges:
Viral vector delivery of EGFR ligands represents a promising approach:
| Vector | Ligand | Approach | Stage |
|--------|--------|----------|-------|
| AAV | EGF | Regulated expression | Preclinical |
| AAV | HB-EGF | Cell-type specificity | Research |
| AAV | TGF-α | Dopaminergic targeting | Preclinical |
Advantages:
| Combination | Rationale |
|-------------|-----------|
| EGFR modulators + LRRK2 inhibitors | Complementary neuroprotection |
| Growth factor + alpha-synuclein targeting | Multi-pathway approach |
| Cell therapy + gene therapy | Enhanced trophic support |
| Company | Therapy | Identifier | Phase | Status |
|---------|---------|------------|-------|--------|
| BrainStorm | NurOwn (ALS) | NCT03280056 | Phase 3 | Completed |
| LCT | NTCELL | ACTRN12615000216549 | Phase 1/2a | Completed |
| Various | AAV-GDNF | Various | Phase 1/2 | Various |
| Athira | Fosgonimeton | NCT04861281 | Phase 2/3 | Recruiting |
| Approach | Stage | Advantages | Challenges |
|----------|-------|-------------|------------|
| EGF peptide fragments | Preclinical | Direct activation | BBB penetration |
| Small molecule activators | Discovery | Oral bioavailability | Selectivity |
| AAV gene therapy | Preclinical | Sustained delivery | Safety concerns |
| MSC cell therapy | Clinical | Proven safety | Variable function |
| Combination approaches | Preclinical | Multi-target | Complexity |
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
Related Analyses: